Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 3B RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE CONTROLLED MULTI-CENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Next Previous
Search
Trial Profile

A PHASE 3B RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE CONTROLLED MULTI-CENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abrocitinib (Primary) ; Dupilumab
  • Indications Atopic dermatitis
  • Focus Registrational; Therapeutic Use
  • Acronyms JADE DARE
  • Sponsors Pfizer

    • Most Recent Events

    • 21 Mar 2023 Results of post hoc Pooled Analysis of JADE COMPARE and JADE DARE assessing efficacy and safety of abrocitinib and dupilumab in patients with moderate-to-severe AD, with or without comorbid asthma or allergic rhinitis. presented at the American Academy of Dermatology annual Meeting 2023
    • 27 Feb 2023 Results of pooled post hoc analysis of two phase 3, randomized trials (n=1195, JADE COMPARE, NCT03720470; JADE DARE, NCT04345367) assessing the effects of abrocitinib and dupilumab on eosinophilia in patients with moderate-to-severe AD, with or without comorbid asthma or allergic rhinitis.presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 30 Aug 2021 According to a Pfizer media release, full results from this study will be submitted for presentation at a future scientific meeting and publication in a medical journal and at the appropriate time, the company intends to share these data with the U.S. Food and Drug Administration (FDA) and other regulatory agencies around the world reviewing submissions for abrocitinib.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top